Executive Summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline

Adams, Kirkwood F.; Lindenfeld, Jo Ann; Arnold, J. Malcolm O.; Baker, David W.; Barnard, Denise H.; Baughman, Kenneth L.; Boehmer, John; Deedwania, Prakash; Dunbar, Sandra B.; Elkayam, Uri; Gheorghiade, Mihai; Howlett, Jonathan G.; Konstam, Marvin A.; Kronenberg, Marvin W.; Massie, Barry M.; Mehra, Mandeep R.; Miller, Alan B.; Moser, Debra K.; Patterson, J. Herbert; Rodeheffer, Richard J.; Sackner‐Bernstein, Jonathan; Silver, Marc A.; Starling, Randall C.; Stevenson, Lynne Warner; Wagoner, Lynne E.

doi:10.1016/j.cardfail.2005.12.001

Cited by 468 publications

(52 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For this reason, we selected metoprolol succinate as representative of β-blockers of proven efficacy in the treatment of HF from randomized controlled trials [1,2,3] and atenolol for β-blockers not recommended for treatment of HF. Atenolol was chosen because of the high prescription rate of this agent in large HF registries in clinical practice [10, 11].…”

Section: Discussionmentioning

confidence: 99%

“…Atenolol was chosen because of the high prescription rate of this agent in large HF registries in clinical practice [10, 11]. In order to avoid potential bias related to choice of doses, we selected doses and frequency of administration of atenolol and metoprolol CR/XL commonly recommended in treatment guidelines [1,2,3, 8, 9], accepted to be equivalent [25] and previously used in comparative studies [30]. Current recommendations for the use of atenolol in hypertension and chronic stable angina is once daily [8, 9] and metoprolol CR/XL for HF is also once daily [1,2,3].…”

Section: Discussionmentioning

confidence: 99%

“…β-Adrenergic receptor blockers (β-blockers) are standard therapy for the medical management of chronic heart failure (HF) [1,2,3]. In patients with HF, chronic β-blockade therapy exerts beneficial effects on left ventricular (LV) function and global LV remodeling, and is associated with improved long-term survival in patients with HF of all etiologies [4, 5].…”

Section: Introductionmentioning

confidence: 99%

“…However, it is not clear whether all β-blockers share these benefits as a ‘class effect’ or whether different formulations exert different effects [6, 7]. To date, only 4 β-blockers, the nonselective β 1 -/β 2 -/α 1 -blocker carvedilol and the selective β 1 -blockers controlled release/extended release (CR/XL) metoprolol succinate, bisoprolol and, more recently, nebivolol, have been shown to be beneficial in large-scale controlled randomized clinical trials and consequently approved for the treatment of HF [1,2,3]. Atenolol, a selective β 1 -blocker, is currently approved as an antihypertensive [8] and anti-ischemic drug [9], but is commonly prescribed ‘off-label’ in patients with HF [10, 11], despite the absence of evidence-based efficacy data in this patient population based on the assumption that all β-blockers share the same salutary effects in the treatment of HF [12,13,14,15].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Atenolol Is Inferior to Metoprolol in Improving Left Ventricular Function and Preventing Ventricular Remodeling in Dogs with Heart Failure

Zacà¹,

Rastogi²,

Mishra³

et al. 2008

Cardiology

View full text Add to dashboard Cite

Objectives: β-Blockers are standard therapy for patients with heart failure (HF). This study compared the effects of chronic monotherapy with 2 different β₁-selective adrenoceptor blockers, namely atenolol and metoprolol succinate, on left ventricular (LV) function and remodeling in dogs with coronary microembolization-induced HF [LV ejection fraction (EF) 30–40%]. Methods: Twenty HF dogs were randomized to 3 months of therapy with atenolol (50 mg once daily, n = 6), metoprolol succinate (100 mg, once daily, n = 7) or to no therapy (control, n = 7). LV EF and volumes were measured before initiating therapy and after 3 months of therapy. The change (Δ) in EF and volumes between measurements before and after therapy was calculated and compared among study groups. Results: In controls, EF decreased and end-systolic volume increased. Atenolol prevented the decrease in EF and the increase in ESV. In contrast, metoprolol succinate significantly increased EF and decreased end-systolic volume. ΔEF was significantly higher and Δend-systolic volume significantly lower in metoprolol succinate-treated dogs compared to atenolol-treated dogs (EF: 6.0 ± 0.86% vs. 0.8 ± 0.85%, p < 0.05; end-systolic volume: –4.3 ± 0.81 ml vs. –1 ± 0.52 ml, p <0.05). Conclusions: In HF dogs, chronic therapy with atenolol does not elicit the same LV function and remodeling benefits as those achieved with metoprolol succinate.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Atenolol Is Inferior to Metoprolol in Improving Left Ventricular Function and Preventing Ventricular Remodeling in Dogs with Heart Failure

Zacà¹,

Rastogi²,

Mishra³

et al. 2008

Cardiology

View full text Add to dashboard Cite

show abstract

“…It is a diagnosis characterized by increased mortality rates and hospitalizations as well as poor quality of life [2]. It is already the leading cause of deaths in men and the second leading cause of deaths in women in the African region [3].…”

Section: Introductionmentioning

confidence: 99%

Health Related Quality of Life among Patients with Ischaemic Heart Disease in Kano, Nigeria

Ms¹,

Sm²,

Mi³

et al. 2016

Vasc Med Surg

View full text Add to dashboard Cite

The study examined the quality of life of patients with Ishaemic Heart Diseases (IHD). IHD has been projected to be one of the primary causes of disability and morbidity in many developing countries around the globe. The disease is therefore a vital indicator of patient morbidity and long term disability. It is associated with significant physical, emotional, social and cognitive consequences and contributes greatly to escalating cost of health care. A cross-sectional study design was employed, and a purposive sampling technique was used to recruit the total sample size of eighty. The data was obtained using a standardized data collection form of Short Form Health Survey (SF-36). The data was analyzed using SPSS version 16. The study revealed that (63.7%) of the subjects were between the age group of 61-80 years, and 47.5% had no western education. The study showed that hypertensive disorders, depressive ailments and history of cigarette smoking were the major contributing factors to poor quality of life. The study concluded that there is an overwhelming limited quality of life in patients with IHD. Therefore, it is recommended that health education, non pharmacological programs, and improvement in the health care sector is needed to achieve promising results.

show abstract

A Method of Determining the Dose of Digoxin for Heart Failure in the Modern Era

Bauman¹

2006

Arch Intern Med

View full text Add to dashboard Cite

Executive Summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline

Cited by 468 publications

References 95 publications

Atenolol Is Inferior to Metoprolol in Improving Left Ventricular Function and Preventing Ventricular Remodeling in Dogs with Heart Failure

Atenolol Is Inferior to Metoprolol in Improving Left Ventricular Function and Preventing Ventricular Remodeling in Dogs with Heart Failure

Health Related Quality of Life among Patients with Ischaemic Heart Disease in Kano, Nigeria

A Method of Determining the Dose of Digoxin for Heart Failure in the Modern Era

Contact Info

Product

Resources

About